The research team, led by Mitesh S. Amin, M.D., a resident in the Department of Internal Medicine at the VCU School of Medicine, developed the guidelines, which appear in the July 26 issue of the Journal of the American Medical Association.
“There is limited information to direct patient management after an implantable device has been subject to an FDA advisory,” said Kenneth Ellenbogen, M.D., director of VCU’s cardiac electrophysiology lab and senior author of the study. “These guidelines can give physicians a better understanding of the risks and benefits of device replacement compared to continued clinical follow-up.”
In the analysis, the researchers considered the potential outcomes in deciding whether to immediately replace a device under advisory or to continue follow-up without replacement.
In determining the best management approach, the researchers constructed a decision analysis model to evaluate the risks and benefits associated with device replacement or continued monitoring.
The study considered variables including indications for device implantation, anticipated course following device failure, device failure rates from the advisory and device replacement mortality rates per procedure.
According to Ellenbogen, the findings suggest device replacement in the setting of an advisory is not inconsequential and frequently has a greater risk than continued device follow-up. The decision to replace a recalled device should be based primarily on the device failure rate, the degree of patient dependency and the anticipated mortality from device replacement.
“We ultimately want the best care for patients with implantable devices and having a rational mechanism to approach these patients is critical to patient care,” said Ellenbogen.
Ellenbogen and Amin collaborated with Mark Wood, M.D., VCU professor of internal medicine, and David Matchar, M.D., professor of medicine at Duke University.
According to the study, there are approximately 2 million patients with ICDs and pacemakers worldwide that often are implanted for life threatening conditions – pacemakers for patients with complete heart block and ICDs to provide therapy for patients at risk for cardiac arrest. Advisories typically arise from unanticipated device failures which are identified after product release and widespread clinical use.
EDITOR’S NOTE: For a copy of the study, contact JAMA at firstname.lastname@example.org, or call 312-464-JAMA.
Malorie Janis | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
20.03.2018 | Earth Sciences
20.03.2018 | Physics and Astronomy
20.03.2018 | Information Technology